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Abstract
Background: The prevalence, morbidity, and mortality of inflammatory lung diseases such as asthma, chronic
obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are increasing in women. There is a dearth of data
on the biological mechanisms to explain such observations. However, some large epidemiologic studies suggest
that lung function fluctuates during the menstrual cycle in female patients with airways disease but not in women
without disease, suggesting that circulating estradiol and progesterone may be involved in this process.
Discussion: In asthma, estradiol shuttles adaptive immunity towards the TH2 phenotype while in smokers
estrogens may be involved in the generation of toxic intermediate metabolites in the airways of female smokers,
which may be relevant in COPD pathogenesis. In CF, estradiol has been demonstrated to up-regulate MUC5B gene
in human airway epithelial cells and inhibit chloride secretion in the airways. Progesterone may augment airway
inflammation.
Summary: Taken together, clinical and in-vivo data have demonstrated a sex-related difference in that females
may be more susceptible to the pathogenesis of lung diseases. In this paper, we review the effect of female sex
hormones in the context of these inflammatory airway diseases.
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Background
The sex differences in the epidemiology of asthma, COPD
and CF
There is an epidemic of inflammatory lung diseases such
as asthma, chronic obstructive pulmonary disease
(COPD) and cystic fibrosis (CF). Although these condi-
tions have distinct pathophysiologies, women for largely
unknown reasons are increasingly becoming more pre-
valent and experiencing excess morbidity and mortality
from these disorders. For instance, in the United States
(U.S.) and elsewhere, more than 60% of all adult patients
with asthma are women, and female compared to male
asthmatics are 50% more likely to have physician visits,
35% more likely to experience hospitalizations and 40%
more likely to die from asthma [1]. Although men have
higher prevalence of COPD than women, the increased
rates of cigarette smoking in females within the last
several decades have been associated with steadily
increasing rates of COPD in females [2]. In 2000, for
the first time, the number of women dying of COPD in
the United States surpassed the number of men [3].
Even in cases in which cigarette smoking is implicated,
women develop COPD after smoking fewer number of
cigarettes per lifetime (i.e. less pack-years of smoking)
[4] and are two to three times more likely to experience
hospitalization than are male patients [5]. Among first-
degree relatives of patients with severe COPD, female
smoking relatives demonstrate significantly lower lung
function compared to male smoking relatives [6]. In
patients with severe COPD with oxygen dependence,
women have a 50% increase in the risk of mortality
compared to men [7]. Finally, although CF is a rare
genetic disorder that affects both men and women, for
largely unclear reasons, female patients have shorter life
expectancy compared to male patients (Figure 1). Col-
lectively, these epidemiologic data suggest that female
gender is a significant risk factor for morbidity and mor-
tality in inflammatory lung diseases and raise the possi-
bility that sex-related hormones may be important in
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though the mechanisms by which this occurs may differ
between these disorders. In this paper, we will examine
the potential role of estrogen and progesterone in the
pathogenesis of these disorders.
Biology of sex hormones
Estrogen and progesterone
Steroid hormones are primarily synthesized in the
gonads, adrenal glands, and the feto-placental unit [9].
Cholesterol is the common precursor of all steroid hor-
mones where it is first converted to pregnenolone by
P450-linked side chain cleaving enzyme (P450ssc)
(Figure 2A). Pregnenolone is then converted to proges-
terone, which is used to synthesize androgens and estro-
gens [10]. Estrogens are derived from androgens by the
addition of an aromatic A ring, through a reaction that
is catalyzed by the enzyme aromatase [10,11]. Estrogen
and progesterone are multi-ringed structures with dis-
tinct functional groups (Figure 2B, C, D, E). Unlike pro-
gesterone, there are three major naturally occurring
e s t r o g e n si nw o m e n :1 )e s t r i o l ,2 )e s t r a d i o l ,a n d3 )
estrone. In humans, estriol is the predominant estrogen
in pregnant women, while estradiol is the predominant
form in the non-pregnant premenopausal women and
estrone is the predominant estrogen in the menopausal
females. Sex steroid hormones act via their own unique
receptors: estrogen receptor (ER-a or ER-b), progester-
one receptor (PR-A or PR-B), and an androgen receptor
(AR) [12]. Estradiol binds with a higher affinity to ER
than its metabolic products such as estrone and estriol
[13]. All sex steroid hormone receptors have been
shown to be expressed in lung tissue [14,15].
Sex hormones and menstrual cycle
Four main hormones characterize the menstrual cycle:
estradiol (E2), progesterone (P), luteinizing hormone,
and follicle stimulating hormone. On average, the men-
strual cycle is 28 days and is divided in two phases: the
follicular (Day 1-13) and the luteal phase (Day 14-28).
The onset of ovulation is defined by a surge in estradiol
on day 14. Menstruation and the late luteal phase are
characterized by low serum levels of estradiol (~0.15
nM) and progesterone (~9.54-31.81 nM); whereas ovula-
tion is marked by high circulating levels of estradiol
(~0.37-1.47 nM) and low levels of progesterone (~0.95-
9.54 nM) (Table 1). During the luteal phase, estradiol
levels range from 0.15-0.92 nM, whereas progesterone
levels increase from 9.54-31.81 nM and drop back to
lower levels prior to menstruation. However during
menopause, estradiol and progesterone levels in both
genders significantly reduced to levels below those in
the menstruation phase.
Figure 1 Median survival ages in both sexes in CF from 1977-2002. Obtained from the Canadian Cystic Fibrosis Foundation, Report of the
Canadian Patient Data Registry 2002, Toronto, Ontario [8].
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via SHBG
Sex hormone binding globulin (SHBG) is an important
steroid hormone binding protein in human plasma and
regulates sex hormone delivery to tissues and cells [17].
Plasma SHBG is produced primarily in hepatocytes,
which is a glycosylated isoform of SHBG [18] and is
produced by the Sertoli cells [19]. In biological fluids,
SHBG exists as a homodimer with a separate steroid-
binding pocket and a calcium-binding site in each
monomer [20] and binds to both androgens and estra-
diol with nanomolar affinities [21]. In normal men and
women, between 40-65% of circulating testosterone (T)
and between 20-40% of circulating estradiol (E2) is
bound to SHBG [22]. SHBG regulates tissue delivery of
sex hormones by binding them and retaining them in
the circulatory pool, where they are relatively inert.
However, once the sex hormones dissociate from SHBG,
they can escape the blood stream, and bind with the
intracellular androgen or estrogen receptors, causing
changes in gene expression of cells [17]. It is thus gener-
ally accepted that only the non-bound hormone is biolo-
gically active [23]. SHBG is considered as an estrogen
amplifier because T preferentially binds with SHBG,
causing more E2 to remain unbound [17].
Sex hormone receptors: lung physiology
For many years, we have known that estrogen and proges-
terone receptors are responsible for sexual development
[24] but their effect beyond the reproductive system is
becoming increasingly recognized. There are two types of
estrogen receptors (ER), two types of progesterone recep-
tors (PR): ER-a,E R - b,P R - Aa n dP R - B ,a l lo fw h i c ha r e
expressed in rats [25], mouse [26], and humans [27].
While androgen receptor (AR) is expressed primarily in
mammalian reproductive tissues [28], ER-a,E R - b,P R - A
and PR-B expression have been noted in not only in the
mammalian female and male reproductive tracts, but also
in the female mammary glands, bone, cardiovascular tis-
sues, lung, and the brain [14,24]. In the lungs, the expres-
sion of ER-b protein is twice as that of ER-a [29]. Most of
Figure 2 Used with permission from the American Physiological Society. A) Overview of the sex steroid hormone biosynthetic pathway
and associated nuclear receptors. P450ssc, P450-linked side chain cleaving enzyme; CYP17, cytochrome P450 17; 3b-HSD, 3b-hydroxysteroid
dehydrogenase; 17b-HSD, 17b-hydroxysteroid dehydrogenase; PR, progesterone receptor; AR, androgen receptor; ER, estrogen receptor. B)
Progesterone, C) estriol, D) estradiol, E) estrone [9].
Table 1 Female hormone levels throughout the menstrual cycle [16]
Phases 17b-estradiol (nM) Progesterone (nM)
Day 1-13 (follicular) ~0.15-0.37 (40-100 pg/ml) ~0.95 (300 pg/ml)
Day 14 (Ovulation) ~0.37-1.47 (100-400 pg/ml) ~0.95-9.54 (300-3000 pg/ml)
Day 15-28 (luteal) ~0.15-0.92 (40-250 pg/ml) ~9.54-31.81 (3000-10,000 pg/ml)
Tam et al. BMC Women?’?s Health 2011, 11:24
http://www.biomedcentral.com/1472-6874/11/24
Page 3 of 9the expression is found in the cytoplasm but minor
expression has also been noted in the mitochondria and
nucleus [29]. ER-a and ER-b belong to a super-family of
nuclear hormone receptors, many of which are ligand-acti-
vated transcription factors that regulate gene expression
by binding to the promoter region of genes [24]. These
receptors contain an N-terminal DNA binding domain
and a C-terminal ligand binding domain (LBD) for estro-
gen [24]. Studies in mice in which ER-a and ER-b were
deleted revealed that both types of ER are required for the
formation of complete alveolar units in females. ER-a
ensures that the lungs differentiate properly during devel-
opment, leading to normal numbers of alveoli per surface
area. ER-b, on the other hand, modulates development of
extracellular matrix, leading to normal elastic tissue recoil
pressure in the lungs [30,31]. Furthermore, ER-a, but not
ER-b, has been demonstrated to mediate an anti-inflam-
matory response when challenged by carrageenan (CAR)
in mice [32]. Upon activation by E2, ER-a inhibited the
intracellular trafficking of nuclear factor-B, thereby pre-
venting the expression of inflammatory genes [33].
Mechanism of estrogen receptor activation in the lungs
The exact mechanism by which E2 modulates cell signal-
ing pathways is not completely known and there may be
multiple cell signaling pathways by which sex hormones
affect gene regulation and expression. According to the
free hormone hypothesis, unbound sex steroids freely dif-
fuse across cell surface membranes [23]. Binding of estro-
gen to the ligand binding domain of the ER causes a
conformational change in the receptor, which results in
dimerization of ER and translocation to the nucleus [24].
The activated receptor/DNA complex then binds to speci-
fic promoter sequences of DNA called hormone response
elements (HREs) and recruits other cofactors from the
nucleus, which results in transcription of DNA down-
stream from the HRE [24]. An alternate hypothesis sug-
gests that even E2 bound to SHBG are metabolically
active. It is now well recognized that sex steroids target tis-
sues containing membrane-binding sites that can bind
with SHBG [34]. In prostate [35] and breast cancer cells, it
has been shown that by binding to this site, SHBG triggers
cAMP-dependent signaling causing upregulation of adenyl
cyclase and other downstream signaling molecules. It is
important to note that these data were generated in vitro
using isolated epithelial cells and not in the context of
these cells in vivo. Thus, the exact cell signaling pathway
of sex hormones remains unknown.
Discussion
How sex hormones may modulate COPD
Sex hormone on cigarette smoke metabolism
A variety of animal models have been used to examine
potential sex-related differences in the risk of inflamma-
tory lung diseases. For example, chronic exposure of mice
to cigarette smoke has led to the development of emphy-
sematous-like changes in alveolar structure, and these
changes develop more rapidly in females than in males [9].
It is important to note that cigarette smoke is made up of
more than 4,000 different chemicals. After inhalation,
these chemicals are metabolized in two different phases:
Phase I and Phase II. Phase I is mediated largely by cyto-
chrome P450 (CYP) enzymes, which are a family of xeno-
biotic enzymes that are responsible for de-toxifying
cigarette smoke and other environmental irritants into
intermediate metabolites. These metabolites in turn are
conjugated by Phase II enzymes and excreted. The rate-
limiting step in most cases is Phase II. Thus, if there is
under-expression of Phase II enzymes or complete satura-
tion of their binding sites, CYP-based metabolites accumu-
late in the lung. Because some intermediate metabolites
are as toxic and others are even more toxic than their par-
ent constituents, lungs may suffer oxidant damage through
a process called bioactivation unless there is excellent co-
ordination of Phase I and Phase II enzymes. Estradiol up-
regulates CYP enzymes without necessarily altering the
expression of Phase II enzymes, making the female lungs
more susceptible to oxidant damage in response to cigar-
ette smoke. This concept is supported by animal experi-
ments. For instance, Van Winkle et al. showed that the
lungs of female mice were more susceptible to naphtha-
lene, a prominent component of side stream cigarette
smoke, compared to male mice [36]. Female lungs of rats
had higher expression of CYP enzymes and demonstrated
increased accumulation of potent oxidants from naphtha-
lene metabolites [37]. Interestingly, in humans, the two
CYP enzymes that are up-regulated by cigarette smoke are
CYP1A1 and CYP1B1, which are regulated by ER-a [38].
Stimulation of estrogen receptors in the lungs increases
p r o t e i ne x p r e s s i o no fC Y P 1 A 1 by twofold [39]. CYP1A1
has been demonstrated to have high activity for 17b-estra-
diol 2-hydroxylation, followed by 15a-, 6a-, 4-, and 7a-
hydroxylation [40]. 2-hydroxylated estrogens are suggested
to be anti-carcinogens, whereas 4- and 16a-hydroxylated
estrogens may enhance cancer development [41-43]. Inter-
estingly, 2-hydroxyestrogen but not 16a-hydroxyestrogen
has increased clearance rate from the circulation of pre-
menopausal females smokers [44,45], suggesting a differ-
ential effect of estrogen metabolism. The increased CYP
expression is related to increased levels of estradiol [46]
and increased metabolism of cigarette smoke to generate
oxidants/oxidizers [47], suggesting that female sex hor-
mone contributes to oxidative stress and greater airway
injury.
How sex hormones may modulate asthma
Animal Models for Asthma
When challenged with allergen, female compared to
male mice mount an enhanced allergic response,
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specific IgG1 and IgE [48] and increased airway inflam-
mation [49]. Ovariectomized rats, on the other hand, are
protected from increased airway inflammation related to
allergens [50]. Estrogen replacement in these ovariecto-
mized rats reestablishes airway inflammation to levels
found in intact females [50]. Collectively, these data sug-
gest that female hormones augment airway inflamma-
tion in the presence of allergens. One potential
mechanism for this response is estrogen-mediated devia-
tion in helper T cells towards a TH2p h e n o t y p e .
Another mechanism is that female hormones down-reg-
ulate the expression of regulatory T (Treg) cells [51],
which play an important role in regulating TH2
responses [52]. Estradiol may also up-regulate early
phase pro-inflammatory cytokines such as IL-1b and
TNF-a and down-regulate anti-inflammatory cytokines
such as IL-10 [53]. Consistent with this notion, Huber
and Pfaeffle showed that male mice transfected with
Coxsackievirus B3 predominantly mounted a TH1c e l l
phenotypic response, while female mice mounted a vig-
orousTH2 cell phenotypic response [54]. Interestingly,
when male mice were given estradiol, the ratio of IL-2/
IFN-g to IL-4-producing cells became nearly equal, sug-
gesting that estrogen promotes a TH2r e s p o n s e[ 5 4 ] .
Progesterone, on the other hand, significantly increases
the expression of IL-10, IL1-b,a n dT N F - a in the lungs,
and augments the release of IL-4 by bone marrow cells
[53], which may lead to eosinophilia. The existence of
such dual hormone effects suggests that the balance
between estradiol and progesterone may be critical in
host responses to environmental allergens [53]. It should
be noted, however that the ovary generates a large num-
ber of cytokines and other factors that modulate the
inflammatory process and affect the actions of estradiol
and progesterone [55,56].
Sex hormones and adaptive immunity
Differences in male and female immune responses have
been recognized for some time [54]. Females generally
mount better humoral immunity than males, while
males demonstrate enhanced cellular immune responses
[57,58]. These differential immune responses may be
important in autoimmune diseases. Helper T cells origi-
nate from hematopoietic stem cells in the bone marrow,
mature in the thymus and act in many different tissues
and organs. The two major subsets of helper T cells are
TH1a n dT H2 cells. Naïve T cells differentiate into TH1
cells in the presence of IFN-g and IL-12, which are
secreted by dendritic cells in response to bacterial and
viral challenge. TH1c e l l sp r o d u c eav a r i e t yo fd i f f e r e n t
cytokines including IFN-g and IL-2 and regulate the
cell-mediated immune response [59,60]. In response to
extracellular parasites and allergens, dendritic cells pro-
duce IL-4, which promotes the TH2 lineage. TH2 cells,
dissimilar to TH1 cells, produce mostly IL-4, -5, -10 and
-13 to promote IgG, IgA, and IgE antibody isotype
responses [61].
Unlike the animal models, immunological modulation
by sex hormones in human inflammatory diseases is
more complex. However, there are data suggesting that
certain inflammatory diseases can modulate the TH1/
TH2 response in humans. For example, patients with
systemic lupus erythematosus (SLE) demonstrate a
unique pattern of estrogen production and metabolism
[62]. SLE is characterized by elevated aromatase enzyme
activity and cytochrome p450 isoenzyme (CYP1B1),
increased expression of the CD4
+ TH2 response and a
relative under-expression of the CD4
+ TH1r e s p o n s e
[62]. Estrogen is known to be an inducer of aromatase
that converts androgen to estrogens. CYP1B1 then con-
verts estrogen to 16a-hydroxyestrone, which is the most
biologically active serum estrogen with the most potent
immunomodulatory effects [62]. Estrogen can also sti-
mulate secretion of IL-4, -5, -6, and -10 by TH2 lympho-
cytes, while androgens promote the production of IL-2
by TH1 cells [62]. Taken together, the relative balance
between estrogen and androgen in the circulation may
influence the TH1/TH2 lineage and modulate the overall
inflammatory response.
Clinical overview of asthma
It is well known that before puberty the incidence of
asthma is higher in boys than in girls, but following
puberty, the pattern switches such that by adulthood,
the prevalence of asthma is nearly 50% higher in women
than in men [63]. It is also well known that asthma
severity fluctuates over the course of the menstrual
cycle [64]. The incidence of asthma tends to decrease
after menopause [65] but hormone replacement therapy
following menopause is associated with an increased
risk of asthma in non-smokers but not with newly diag-
nosed COPD [66,67], suggesting that sex hormones may
play a more important role in the development and pro-
gression of asthma.
Sex hormones on lung function in asthma
Both forced expiratory volume in one second (FEV1)
and forced vital capacity (FVC) are the lowest following
ovulation in the peri-ovulatory phase of the menstrual
cycle. During this phase, circulating estradiol levels are
relatively high and progesterone levels are moderate.
FEV1 and FVC are the greatest during the peri-men-
strual period when estradiol and progesterone levels are
at their lowest [68]. Consistent with the observation,
Zimmerman and colleagues showed that the highest
rates of emergency department visits for asthma
occurred during the pre-ovulatory phase of the men-
strual cycle [69]. Although the exact mechanism for
these observations are unknown, as previously stated,
both progesterone (at any concentration) and estrogen
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phenotype, which is likely to be important in asthma
pathogenesis.
Sex hormones on exhaled nitric oxide in women
An important biomarker of airway inflammation in
asthma is nitric oxide (NO). NO is synthesized by acti-
vated alveolar macrophages (AM) through the actions of
an inducible form of nitric oxide synthase (iNOS) [70].
AM effects bacterial and viral killing by releasing NO
and other reactive oxygen and nitrogen species [71].
However, in asthma, this process is dysregulated such
that even the absence of microbial products, NO path-
ways in the airways are enhanced.
Provocatively, in a small study of pre-menopausal
women not using oral contraceptives, Mandhane et al.
showed that exhaled NO concentrations were positively
related to serum progesterone (p < 0.05) but inversely
related to serum 17b-estradiol levels [72]. Similarly, Farha
et al showed that exhaled NO concentrations were highest
in the luteal phase (when serum progesterone levels are
expected to reach their peak). Suppression of the men-
strual cycle with the use of oral contraceptives, on the
other hand, abolished these relationships. Together, these
data suggested that progesterone may be a very important
regulator of airway inflammation in female asthmatics.
How sex hormones may modulate Cystic Fibrosis
Sex hormone on mucus production
Accumulation of thick, tenacious mucus is a hallmark of
cystic fibrosis (CF) and has a central role in CF patho-
physiology [73]. Mucus clearance plays an important
role in innate immunity in the mammalian lung [74].
Excess sputum production in the lung is one of the key
factors in overwhelming ciliary clearance and obstruct-
ing the airways, thereby contributing to morbidity and
mortality in CF and other inflammatory lung diseases
[75]. Mucins are upregulated by pathogens, inflamma-
tory mediators, and toxins, which when dysregulated
can exacerbate chronic airway diseases [76,77]. Expres-
sion of mucin genes is increased by inflammatory med-
iators, such as lipopolysaccharide (LPS) [78], TNF-a
[79], IL-1 [79], IL-17 [80] and b neutrophil elastase [81].
In addition to these inflammatory mediators, it is
known that sex hormones such as estrogen can also up-
regulate MUC5B gene expression in normal human air-
way epithelial cells [82]. MUC5B is one of the major
mucins in the human airway submucosal glands [83].
Estrogen is not the only regulator of MUC5B but also
regulates a wide diversity of genes involved in extracel-
lular matrix, general cell growth, and differentiation pro-
cesses [24]. Taken together, estradiol may have the
potential to augment mucin production resulting in
reduced clearance in CF.
Sex hormone on Ca
+2-activated Cl
- secretion
An in-vitro study [84] has shown that high circulating
levels of estradiol reduces Ca
+2-activated Cl
- secretion
by airway epithelial cells in culture, thereby disrupting
ion and water balance and leading to thick, tenacious
mucus. Clinical studies have confirmed that Ca
+2-acti-
vated Cl
- secretion is decreased in women with CF at
times when 17b-estradiol levels are high [69]. Estadiol
mediates this effect by inhibiting Ca
+2 influx and sig-
naling in both non-CF and CF airway epithelia [74].
Moreover, estrogen also appears to inhibit the uridine
triphosphate-mediated Cl
- secretion in both women
with CF and normal, healthy women [74]. Experiments
revealed that a four-fold increase in estradiol was
accompanied by a 50% inhibition of UTP-stimulated
Cl
- secretion in vivo [74]. Since the CF lung disease is
characterized by poor Cl
- secretion and water retention
in the airways [74], it is likely that the estrogen-related
disturbance in Cl
- secretion via the Ca
+2-activated
channels and other pathways can cause marked pertur-
bations in mucociliary clearance, and accumulation of
thick mucus in the airway, resulting in disease progres-
sion [85].
Sex hormones on lung function in CF
As with asthma, menstrual cycles may also affect lung
function in female patients with CF but not in the
same phasic manner [86]. Unlike in asthmatics who
demonstrate best lung function in the peri-menstrual
period, female CF patients have the highest lung func-
tion during the luteal phase and the lowest lung func-
tion during the pre-ovulatory phase [87]. Johannesson
showed that FEV1 was 66% of predicted in female CF
patients during the luteal phase, while it was only 63%
during ovulation (P < 0.01) [86], which interestingly is
associated with increasing levels of estradiol. The dif-
ferences in the swings in lung function during the
menstrual period between asthmatics and CF patients
may relate to the relative importance of mucus pro-
duction in their pathophysiology. Although mucus
production and clearance are thought to be important
both diseases, in CF, it is has a pre-eminent role,
while in asthma, it is believed to have a more comple-
m e n t a r yr o l ei nd i s e a s ep r o g r e s s i o n .B yu p - r e g u l a t i n g
MUC5B expression, high estradiol levels during the
pre-ovulatory phase may significantly enhance mucus
production (through the mechanisms discussed in the
previous section) and lead to worsening of airflow
limitation in CF. Furthermore, 17b-estradiol in high
physiological concentrations inhibits local production
of IL-8 by up-regulating secretory leucoprotease inhi-
bitors [88], which may diminish the ability of the
female respiratory tract to contain bacterial infections
in CF.
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Women are relatively more prevalent in the epidemiology
of asthma, CF and COPD and appear in general to have
worse prognosis than their male counterparts. The exact
mechanism of this process is still uncertain. Emerging
data suggest that female sex hormones play a role in
these inflammatory airway conditions, through different
but related mechanisms. Studies have shown that estro-
gen promotes a TH2 response, while androgen promotes
aT H1 response, which may be relevant in asthma. Estra-
diol inhibits Cl
- secretion in the CF lung and up-regulates
mucus production, which may be very relevant in CF.
Cigarette smoke is de-toxified through Phase I and Phase
II enzymes and estrogens may preferentially up-regulate
Phase I enzymes, leading to accumulation of toxic meta-
bolites through a process called bioactivation. This may
be relevant in the pathophysiology of COPD. Although
less well studied than estrogen, progesterone may also
play relevant roles in inflammatory airway disease by
amplifying airway inflammation. With the rise in the bur-
den of these diseases in women worldwide, there is a
pressing need to better understand the biological roles of
sex hormones in modulating airway inflammation,
mucus production and cigarette de-toxification and other
processes relevant to COPD, asthma and CF.
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